JPMorgan Chase & Co. reiterated their overweight rating on shares of AstraZeneca (LON:AZN) in a research note issued to investors on Monday, Borsen Zeitung reports. JPMorgan Chase & Co. currently has a GBX 7,900 ($103.23) target price on the biopharmaceutical company’s stock.
A number of other research analysts have also issued reports on the company. Citigroup reiterated a buy rating and issued a £100 ($130.67) target price (up from GBX 7,000 ($91.47)) on shares of AstraZeneca in a report on Wednesday, September 11th. Deutsche Bank lifted their target price on AstraZeneca from GBX 7,600 ($99.31) to GBX 7,800 ($101.92) and gave the company a buy rating in a report on Monday, September 9th. Goldman Sachs Group set a GBX 5,500 ($71.87) target price on AstraZeneca and gave the company a sell rating in a report on Monday, September 2nd. Jefferies Financial Group reiterated a neutral rating on shares of AstraZeneca in a report on Thursday, August 29th. Finally, Shore Capital reiterated a buy rating on shares of AstraZeneca in a report on Tuesday, August 27th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have given a buy rating to the company. AstraZeneca currently has a consensus rating of Hold and a consensus price target of GBX 7,050 ($92.12).
LON:AZN opened at GBX 6,947 ($90.77) on Monday. The firm has a market cap of $91.14 billion and a PE ratio of 40.58. The stock has a fifty day moving average price of GBX 7,180.61 and a 200 day moving average price of GBX 6,406.21. AstraZeneca has a 12-month low of GBX 5,312 ($69.41) and a 12-month high of GBX 7,583 ($99.09). The company has a current ratio of 0.95, a quick ratio of 0.74 and a debt-to-equity ratio of 144.48.
The firm also recently declared a dividend, which was paid on Monday, September 9th. Shareholders of record on Thursday, August 8th were paid a GBX 71.90 ($0.94) dividend. This represents a yield of 1.07%. The ex-dividend date was Thursday, August 8th. AstraZeneca’s dividend payout ratio is presently 1.28%.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Recommended Story: How is Preferred Stock Different from Common Stock?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.